These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 29808341)

  • 21. Multiple imputation for early stopping of a complex clinical trial.
    Betensky RA
    Biometrics; 1998 Mar; 54(1):229-42. PubMed ID: 9544518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decision-making when data and inferences are not conclusive: risk-benefit and acceptable regret approach.
    Hozo I; Schell MJ; Djulbegovic B
    Semin Hematol; 2008 Jul; 45(3):150-9. PubMed ID: 18582621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Curtailment in single-arm two-stage phase II oncology trials.
    Kunz CU; Kieser M
    Biom J; 2012 Jul; 54(4):445-56. PubMed ID: 22610516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stochastically curtailed phase II clinical trials.
    Ayanlowo AO; Redden DT
    Stat Med; 2007 Mar; 26(7):1462-72. PubMed ID: 16900560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bayesian predictive approach to interim monitoring in clinical trials.
    Dmitrienko A; Wang MD
    Stat Med; 2006 Jul; 25(13):2178-95. PubMed ID: 16007570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exact, conditional, and predictive power in planning clinical trials.
    Moussa MA
    Control Clin Trials; 1989 Dec; 10(4):378-85. PubMed ID: 2691205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving Probabilities of Correct Interim Decision in Population Enrichment Designs.
    Götte H; Donica M; Mordenti G
    J Biopharm Stat; 2015; 25(5):1020-38. PubMed ID: 24914474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An extension of Bayesian expected power and its application in decision making.
    Liu F
    J Biopharm Stat; 2010 Sep; 20(5):941-53. PubMed ID: 20721783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial.
    Hughes S; Cuffe RL; Lieftucht A; Garrett Nichols W
    Pharm Stat; 2009; 8(1):25-37. PubMed ID: 18383194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of five approaches to decision-making for a first clinical trial of efficacy.
    Kirby S; Chuang-Stein C
    Pharm Stat; 2017 Jan; 16(1):37-44. PubMed ID: 27678332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data.
    Shimura M; Gosho M; Hirakawa A
    Stat Med; 2017 Jun; 36(13):2067-2080. PubMed ID: 28211076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
    Walter SD; Han H; Briel M; Guyatt GH
    Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating conditional probabilities of terrorist attacks: modeling adversaries with uncertain value tradeoffs.
    Levine ES
    Risk Anal; 2012 Feb; 32(2):294-303. PubMed ID: 21801187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of program success for programs with multiple trials in binary outcomes.
    Wang M; Liu GF; Schindler J
    Pharm Stat; 2015; 14(3):172-9. PubMed ID: 25645143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.